Intradetrusor botulinum toxin as the first-line treatment for neurogenic detrusor overactivity: Pro

Prog Urol. 2023 Mar;33(4):174-175. doi: 10.1016/j.purol.2022.12.010. Epub 2023 Jan 7.

Authors

P Denys¹, C Joussain²

Affiliations

¹ UMR Inserm 1179, service de neuro-urologie et andrologie, hôpital Raymond-Poincaré, université de Versailles Saint-Quentin-Paris-Saclay, 104, boulevard Raymond-Poincaré, 92380 Garches, France. Electronic address: pierre.denys@aphp.fr.
² UMR Inserm 1179, service de neuro-urologie et andrologie, hôpital Raymond-Poincaré, université de Versailles Saint-Quentin-Paris-Saclay, 104, boulevard Raymond-Poincaré, 92380 Garches, France.

PMID: 36624006
DOI: 10.1016/j.purol.2022.12.010

No abstract available

Publication types

Editorial

MeSH terms

Botulinum Toxins, Type A*
Humans
Neuromuscular Agents*
Treatment Outcome
Urinary Bladder, Neurogenic*
Urinary Bladder, Overactive*
Urodynamics

Substances

Botulinum Toxins, Type A
Neuromuscular Agents